Plasma derived fibrin scaffold
 
Platelet releasing growth factors, cytokines and chemokines
 
AutoloGel (platelet rich plasma gel)


The AutoloGel System formulation is designed to provide:

  • Platelet releasate gel containing growth factors, cytokines, and chemokines for cell growth and formation of new tissue 13,14
     
  • Plasma derived fibrin and fibronectin scaffolding for cell migration15
     
  • Proprietary formulation for increased synthesis and assembly of collagen11,16
     
  • Plasma and platelet derived inhibitors of metalloproteinase activity (TIMPs) that combat destructive protease activity17,14
     
  • Human serum albumin to block neutrophil spreading and release of damaging free radicals18
     
  • Proprietary additions to scavenge damaging free radicals19,20
     
  • Plasma gel for a moist wound environment
Non Concentrated Platelet Formulation
Unlike other systems that produce highly concentrated PRP, the AutoloGel System offers the distinct advantage of providing PRP that is not highly-concentrated. Growth factors, cytokines and chemokines regulate processes critical for wound healing by binding and activating cell surface receptors. It is well known that when non-physiologic, high-concentrations of certain growth factors and chemokines are applied to cells, receptors on the cells can be inhibited or shut-down completely. This “more is not always better” reality is supported by clinical trials demonstrating that high concentrations of a growth factor cocktail derived from platelets do not heal chronic wounds as effectively as lower concentrations.25 The methods and formulation provided with the Autologel system were designed to produce a moist fibrin matrix that delivers growth factors, cytokines and chemokines at concentrations relevant for effective wound healing.

Technology
Cytomedix holds the majority of patents that cover the process, formulation and methods for the platelet rich plasma gel process that includes the AutoloGel System and PRP Gel Systems for Treating Damaged tissue such as wounds and bones. We have licensed the patent for production of PRP for surgical and acute use to a range of well known companies such as J&J and Smith & Nephew. Each time a PRP Gel service provider uses an autologous platelet rich plasma gel or the Autologel System, they need a license for a single application use that is issued by Cytomedix.

11 Canty EG, Kadler KE. Procollagen trafficking, processing and fibrillogenesis. Procollagen Journal of Cell Science 118, 1341-1353 (2005)
12 Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care 2008; 21(12):568-75
13 Rozman P, Bolta Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. 2007. Acta Dermatovenerol Alp Panonica Adriat. 16(4): 156-65
14 Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. 2004 Thromb Haemost 91: 4-15
15 Jacobson M, Fufa D, Abreu E, Kevy S, Murray MM. Platelets, but not erythrocytes, significantly affect cytokine release and scaffold contraction in a provisional scaffold model. 2008 Wound Rep. Reg. 16: 370-378
16 Murad S, Grove D, Lindberg KA, Reynolds G, Sivarajah A, Piinnell SR. Regulation of collagen synthesis by ascorbic acid. 1981 Proc. Natl. Acad. Sci. 78(5): 2879-2882
17 Young-Min S, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston T. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud’s phenomenon, and in normal controls. Ann Rheum Dis. 2001 September; 60(9): 846–851
18 Nathan C, Qiao-wen X, Halbwachs-Mecarelli L, Wen Wen J. Albumin Inhibits Neutrophil Spreading and Hydrogen Peroxide Release by Blocking the Shedding of CD43 (Sialophofin, Leukosialin). The Journal of Cell Biology, Volume 122, Number 1, July 1993: 243-256
19 Burgess C. Topical vitamins. 2008. J Drugs Dermatol. 7(7 Suppl): s2-6
20 Li Y, Schellhorn HE. New Developments and Novel Therapeutic Perspectives for Vitamin C. American Society for Nutrition J. Nutr. 137:2171-2184, October 2007
25 Cytomedix data on file
© 2009 Cytomedix.  All Rights Reserved. Site Map | Terms & Conditions